The patent dispute between Swiss pharmaceutical giant Roche and American biotech heavyweight Biogen over Tocilizumab has emerged as a focal point in the global competition surrounding biosimilars.

In March 2025, South Korea’s Ministry of Food and Drug Safety (MFDS) approved a total of 6 new FDCs across multiple therapeutic areas.

In March 2025, the global pharmaceutical sector witnessed a surge of innovation where technology deeply integrates with clinical needs, spanning key areas.

In February 2025, the global pharmaceutical industry witnessed a series of milestone post-marketing collaboration deals.

Our analysis of February data reveals key trends in global clinical-stage biopharmaceutical financing.

In February 2025, the global biopharmaceutical industry remains active in clinical-stage drug financing and collaboration activities.

Our analysis of February data reveals key trends in global preclinical-stage biopharmaceutical financing.

As global healthcare continues to demand innovative therapies, February 2025 has emerged as a critical period witnessing the robust growth of the biopharmaceutical sector.

February 2025 brought a wave of exciting news for innovators in the global healthcare industry.

Hansoh Pharma entered into a strategic collaboration with Merck & Co. worth over $2 billion, granting Merck the exclusive global license for its investigational GLP-1 receptor agonist, HS-10535.

February 2025 witnessed a wave of mergers and acquisitions in the global biopharmaceutical sector.

February saw the first approvals of several important new drugs.